# US 2008/0187535 A1 · Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187535 A1
- Document ID: US20080187535A1
- Status: Published application
- Kind: A1
- Application number: 12/013,011
- Filed: 2008-01-11
- Published: 2008-08-07
- Earliest claimed: 2007-01-15
- Inventors: Normand Blais; Denis Martin; Remi M. Palmantier
- Web page: https://patentgrep.com/patent/US20080187535A1

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001189: {PRAME}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to fusion proteins comprising an antigen derived from the so-called tumour rejection antigen PRAME (also known as DAGE) linked to an immunological fusion partner which provides T helper epitopes, such as, for example protein D from Haemophilus influenzae B, fusion partner proteins comprising fragments of protein D, methods for preparing the same and for formulating vaccines and use of the same for treating a range of cancers.

## Claims

### Claim 1

A fusion protein comprising:
(a) PRAME or an immunogenic fragment thereof, and
(b) a heterologous fusion partner protein derived from protein D, wherein the said fusion partner protein does not include the secretion sequence or signal sequence from protein D.

### Claim 2

A fusion partner protein derived from protein D, in which the fusion partner protein comprises amino acids Met-Asp-Pro at or within the N-terminus of the fusion protein sequence and in which the fusion partner protein does not include the secretion sequence or signal sequence of protein D.

### Claim 3 (depends on 2)

The fusion partner protein of claim 2, in which the protein D sequence comprises or consists of approximately or exactly amino acids 17 to 127, 18 to 127, 19 to 127 or 20 to 127 of protein D.

### Claim 4 (depends on 1)

The fusion partner protein of claim 1 in which one or more amino acids from the protein D fusion partner protein are deleted or replaced by substitution.

### Claim 5 (depends on 4)

The fusion partner protein of claim 4 in which the amino acids are substituted with conservative substitutions.

### Claim 6 (depends on 4)

The fusion partner protein of claim 4 in which 1, 2, 3, 4, 5, 6, 7, 8, 9 or more amino acids are substituted.

### Claim 7 (depends on 1)

The fusion partner protein of claim 1 in which the secretion sequence or signal sequence of protein D refers to approximately amino acids 1 to 16, 17, 18 or 19 of the naturally occurring protein.

### Claim 8 (depends on 1)

The fusion partner protein of claim 1 in which the secretion or signal sequence of protein D is the N-terminal 19 amino acids of protein D.

### Claim 9 (depends on 2)

The fusion protein comprising the fusion partner protein of claim 2.

### Claim 10 (depends on 2)

The fusion protein comprising the fusion partner protein of claim 2 and one or more tumour antigens or immunogenic portions thereof.

### Claim 11 (depends on 9)

The fusion protein of claim 9 comprising the tumour antigen PRAME or an immunogenic portion thereof.

### Claim 12 (depends on 1)

The fusion protein of claim 1 in which the immunogenic fragment or portion of PRAME comprises or consists of one or more of the following epitopes:
VLDGLDVLL;
(PRA100-108; SEQ ID NO: 13)
SLYSFPEPEA;
(PRA142-151; SEQ ID NO: 14)
ALYVDSLFFL;
(PRA300-309; SEQ ID NO: 15)
LYVDSLFFL
(PRA301-309; SEQ ID NO: 16)
and
SLLQHLIGL.
(PRA425-433; SEQ ID NO: 17)

### Claim 13 (depends on 10)

The fusion protein of claim 10 comprising one or more tumour antigen selected from the group consisting of
MAGE 1, MAGE 2, MAGE 3, MAGE 4, MAGE 5, MAGE 6, MAGE 7, MAGE 8, MAGE 9, MAGE 10, MAGE 11, MAGE 12, MAGE B1, MAGE B2, MAGE B3, MAGE B4, MAGE C1, MAGE C2.
or a tumour antigen derivative or an immunogenic portion thereof.

### Claim 14 (depends on 13)

The fusion protein of claim 13 in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids may be deleted from or substituted in the amino acid sequence of the MAGE antigen.

### Claim 15 (depends on 14)

The fusion protein of claim 14 in which 2 amino acids are deleted from the N-terminus of the MAGE sequence.

### Claim 16 (depends on 15)

The fusion protein of claim 15 wherein the antigen is MAGE-A3 or an immunogenic portion thereof, in which the MAGE-A3 antigen comprises or consists of amino acid 3 to 314 of MAGE-A3.

### Claim 17 (depends on 10)

The fusion protein of claim 10 in which the tumour antigen or derivative thereof is selected from one of the following antigens or an immunogenic portion thereof which is able to direct an immune response to the antigen: WT-1. WT-1F, BAGE, LAGE 1, LAGE 2 (also known as NY-ESO-1), SAGE, HAGE, XAGE, PSA, PAP, PSCA, P501S (also known as prostein), HASH1, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and/or Her-2/neu, SSX-2; SSX-4; SSX-5; NA17; MELAN-A; P790; P835; B305D; B854; CASB618 (as described in WO00/53748); CASB7439 (as described in WO01/62778); C1491; C1584; and C1585.

### Claim 18 (depends on 1)

The fusion protein of claim 1, further comprising an affinity tag.

### Claim 19 (depends on 1)

The fusion protein of claim 1 additionally comprising one or more linker sequences between the fusion partner protein and the tumour antigen or immunogenic portion thereof; and/or between the fusion partner protein and a His tail or other affinity tag; and/or between the tumour antigen or immunogenic portion thereof and a His tail or other affinity tag.

### Claim 20 (depends on 1)

A nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein or fusion partner protein of claim 1.

### Claim 21 (depends on 20)

The nucleic acid molecule of claim 20 further comprising a vector.

### Claim 22 (depends on 21)

A host cell transformed with the nucleic acid molecule of claim 21.

### Claim 23 (depends on 20)

A vaccine comprising:
(a) the nucleic acid molecule of claim 20; or
(b) the fusion protein or fusion partner protein encoded by the nucleic acid molecule of claim 20.

### Claim 24 (depends on 23)

The vaccine of claim 23 additionally comprising one or more components selected from the group consisting of: adjuvant, immunostimulatory cytokine, and chemokine.

### Claim 25 (depends on 24)

The vaccine of claim 24 wherein the adjuvant comprises one or more components selected from the group consisting of: 3D-MPL, QS21, and CpG oligonucleotide.

### Claim 26 (depends on 23)

A method for inducing an immune response in a mammal comprising the step of administering to the mammal the vaccine of claim 23.

### Claim 27

(canceled)

### Claim 28 (depends on 22)

A process for producing a fusion protein comprising the step of inducing the host cell of claim 22 to express the fusion protein encoded by the nucleic acid molecule therein.

### Claim 29 (depends on 28)

The process of claim 28 in which the cell is a bacterium.

### Claim 30 (depends on 29)

The process of claim 29 in which the bacterium is E. coli.

### Claim 31 (depends on 28)

The process of claim 28 in which the fusion protein is expressed in a cell as an insoluble protein.

### Claim 32 (depends on 31)

The process of claim 31 further comprising the step of lysing the cell and purifying the expressed fusion protein from the lysed cells.

### Claim 33 (depends on 28)

The fusion protein obtained by or obtainable by the process of claim 28.

### Claim 34 (depends on 23)

A method of treating a patient suffering from cancer comprising the step of administering the vaccine of claim 23.

### Claim 35 (depends on 34)

The method of claim 34 in which the cancer is selected from the group consisting of melanoma, breast, bladder, lung cancer such as NSCLC, sarcoma, ovarian cancer, head and neck cancer, renal cancer, colorectal carcinoma, multiple myeloma, and leukemia including acute leukemia and oesophageal carcinoma.

### Claim 36 (depends on 2)

The fusion partner protein of claim 2 in which one or more amino acids from the protein D fusion partner protein are deleted or replaced by substitution.

### Claim 37 (depends on 36)

The fusion partner protein of claim 36 in which the amino acids are substituted with conservative substitutions.

### Claim 38 (depends on 37)

The fusion partner protein of claim 37 in which 1, 2, 3, 4, 5, 6, 7, 8, 9 or more amino acids are substituted.

### Claim 39 (depends on 2)

The fusion partner protein of claim 2 in which the secretion sequence or signal sequence of protein D refers to approximately amino acids 1 to 16, 17, 18 or 19 of the naturally occurring protein.

### Claim 40 (depends on 2)

The fusion partner protein of claim 2 in which the secretion or signal sequence of protein D is the N-terminal 19 amino acids of protein D.

### Claim 41 (depends on 11)

The fusion protein of claim 11 in which the immunogenic fragment or portion of PRAME comprises or consists of one or more of the following epitopes:
VLDGLDVLL;
(PRA100-108; SEQ ID NO: 13)
SLYSFPEPEA;
(PRA142-151; SEQ ID NO: 14)
ALYVDSLFFL;
(PRA300-309; SEQ ID NO: 15)
LYVDSLFFL
(PRA301-309; SEQ ID NO: 16)
and
SLLQHLIGL.
(PRA425-433; SEQ ID NO: 17)

### Claim 42 (depends on 2)

The fusion protein of claim 2, further comprising an affinity tag.

### Claim 43 (depends on 2)

The fusion protein of claim 2 additionally comprising one or more linker sequences between the fusion partner protein and the tumour antigen or immunogenic portion thereof; and/or between the fusion partner protein and a His tail or other affinity tag; and/or between the tumour antigen or immunogenic portion thereof and a His tail or other affinity tag.

### Claim 44 (depends on 2)

A nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein or fusion partner protein of claim 2.

### Claim 45 (depends on 44)

The nucleic acid molecule of claim 44 further comprising a vector.

### Claim 46 (depends on 45)

A host cell transformed with the nucleic acid molecule of claim 45.

### Claim 47 (depends on 44)

A vaccine comprising:
(a) the nucleic acid molecule of claim 44; or
(b) the fusion protein or fusion partner protein encoded by the nucleic acid molecule of claim 44.

### Claim 48 (depends on 47)

The vaccine of claim 47 additionally comprising one or more components selected from the group consisting of: adjuvant, immunostimulatory cytokine, and chemokine.

### Claim 49 (depends on 48)

The vaccine of claim 48 wherein the adjuvant comprises one or more components selected from the group consisting of: 3D-MPL, QS21 and/or a CpG oligonucleotide.

### Claim 50 (depends on 48)

A method for inducing an immune response in a mammal comprising the step of administering to the mammal the vaccine of claim 48.

### Claim 51 (depends on 46)

A process for producing a fusion protein comprising the step of inducing the host cell of claim 46 to express the fusion protein encoded by the nucleic acid molecule therein.

### Claim 52 (depends on 51)

The process of claim 51 in which the cell is a bacterium.

### Claim 53 (depends on 52)

The process of claim 52 in which the bacterium is E. coli.

### Claim 54 (depends on 51)

The process of claim 51 in which the fusion protein is expressed in a cell as an insoluble protein.

### Claim 55 (depends on 54)

The process of claim 54 further comprising the step of lysing the cell and purifying the expressed fusion protein from the lysed cells.

### Claim 56 (depends on 51)

A fusion protein obtained by or obtainable by the process of claim 51.

### Claim 57 (depends on 47)

A method of treating a patient suffering from cancer comprising the step of administering the vaccine of claim 47.

### Claim 58 (depends on 57)

The method of claim 57 in which the cancer is selected from the group consisting of melanoma, breast, bladder, lung cancer such as NSCLC, sarcoma, ovarian cancer, head and neck cancer, renal cancer, colorectal carcinoma, multiple myeloma, and leukemia including acute leukemia and oesophageal carcinoma.
